Samuel Kintz - Feb 6, 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Feb 6, 2025
Transactions value $
$0
Form type
4
Date filed
2/10/2025, 05:28 PM
Previous filing
Oct 22, 2024
Next filing
Mar 19, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +490K $0.00 490K Feb 6, 2025 Common Stock 490K $22.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.